This company listing is no longer active
Resumen de acción ASP
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Acerus Pharmaceuticals Corporation
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.36 |
| 52 Week High | CA$10.00 |
| 52 Week Low | CA$0.28 |
| Beta | 0.99 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.00% |
| 3 Year Change | -96.40% |
| 5 Year Change | -99.29% |
| Change since IPO | -99.92% |
Noticias y actualizaciones recientes
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14
Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30
Rentabilidad de los accionistas
| ASP | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | 0% | 8.6% | -0.1% |
| 1Y | -96.0% | 49.8% | 6.2% |
Rentabilidad vs. Industria: ASP underperformed the Canadian Pharmaceuticals industry which returned -55.7% over the past year.
Rentabilidad vs. Mercado: ASP underperformed the Canadian Market which returned -5.2% over the past year.
Volatilidad de los precios
| ASP volatility | |
|---|---|
| ASP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Precio estable de las acciones: ASP's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine ASP's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 14 | Ed Gudaitis | www.aceruspharma.com |
Resumen de fundamentos de Acerus Pharmaceuticals Corporation
| Estadísticas fundamentales de ASP | |
|---|---|
| Capitalización bursátil | CA$2.77m |
| Beneficios(TTM) | -CA$38.24m |
| Ingresos (TTM) | CA$4.14m |
0.7x
Ratio precio-ventas (PS)-0.1x
Ratio precio-beneficio (PE)¿Está ASP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ASP | |
|---|---|
| Ingresos | US$3.04m |
| Coste de los ingresos | US$1.33m |
| Beneficio bruto | US$1.71m |
| Otros gastos | US$29.79m |
| Beneficios | -US$28.08m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -3.64 |
| Margen bruto | 56.32% |
| Margen de beneficio neto | -924.33% |
| Ratio deuda/patrimonio | -329.8% |
¿Cómo se ha desempeñado ASP a largo plazo?
Ver rendimiento histórico y comparativa